Related Experiment Video
Updated: Dec 5, 2025
Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant
Published on: October 6, 2023
PI-RADSv2.1: Current status
Stephanie M Walker1, Barış Türkbey1
1Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Abstract:
Multiparametric magnetic resonance imaging (mpMRI) has played an increasing role in the detection and local staging of prostate cancer over the last 15 years. Prostate mpMRI, due to various factors, is prone to high inter-reader variability necessitating standardized reporting guidelines that provide accurate and actionable information to the ordering clinician. The Prostate Imaging-Reporting and Data System version 2.1 (PI-RADSv2.1) was released in March 2019 as an update to PI-RADSv2.0 with the hope of further standardizing the reporting process of prostate mpMRI, improving the detection of clinically significant cancer, reducing the biopsy rate of indolent tumors, and decreasing inter-reader variability. Early data show an improved performance of PI-RADSv2.1 over PI-RADSv2.0. Updates included in PI-RADSv2.1 and its current experience in clinic will be reviewed in this review.
Insights
Multiparametric MRI (mpMRI) for prostate cancer is improving with PI-RADSv2.1. This updated system aims to enhance cancer detection, reduce unnecessary biopsies, and decrease reporting variability for clinicians.
Area of Science:
- Radiology
- Oncology
- Medical Imaging
Background:
- Multiparametric magnetic resonance imaging (mpMRI) is crucial for prostate cancer detection and staging.
- High inter-reader variability in prostate mpMRI necessitates standardized reporting.
Purpose of the Study:
- To review the updates in PI-RADSv2.1 and its clinical experience.
- To assess PI-RADSv2.1's role in standardizing prostate mpMRI reporting.
Main Methods:
- Review of updates in PI-RADSv2.1 compared to PI-RADSv2.0.
- Analysis of early clinical data on PI-RADSv2.1 performance.
Main Results:
- PI-RADSv2.1 aims to improve clinically significant cancer detection.
- PI-RADSv2.1 seeks to reduce biopsies for indolent tumors.
- Early data suggest improved performance of PI-RADSv2.1 over PI-RADSv2.0.
Conclusions:
- PI-RADSv2.1 represents an advancement in prostate mpMRI reporting.
- The system is expected to decrease inter-reader variability and improve diagnostic accuracy.
More Related Videos
08:25Radiation Planning Assistant - A Streamlined, Fully Automated Radiotherapy Treatment Planning System
Published on: April 11, 2018
09:49A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
Published on: April 24, 2020
Related Concept Videos
01:30Radiological Investigation II: MRI and Ventilation Perfusion Scan
Magnetic Resonance Imaging (MRI) and Ventilation Perfusion Scans are two radiological investigations that offer detailed diagnostic images of the body, particularly lung structures.
MRI
MRI uses magnetic fields and radiofrequency signals to distinguish between normal and abnormal tissues. This technology provides a more detailed diagnostic image than CT scans, enabling it to characterize pulmonary nodules, stage bronchogenic carcinoma, and evaluate inflammatory activity in...
01:29Positron Emission Tomography
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
01:13Radiological Investigation III: Pulmonary Angiogram and PET Scan
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...